.jpeg)
The critical momentum to the biomanufacturing sector in India is being spurred by the fact that Danaher India, a subsidiary of world science and technology giant Danaher Corporation, has entered into a strategic alliance with the Translational Health
In an interaction with India Pharma Outlook, Dr. Mohan Keshavamurthy, Principal Director – Renal Sciences at Fortis Healthcare, discusses how robotic surgery is revolutionizing kidney transplants in India by improving surgical precision, reducing war
Apollo Home Healthcare in collaboration with the Apollo Indraprastha Hospitals has launched a integrated palliative care at home service in New Delhi. This is a ground breaking step towards meeting the increasing demands for compassionate...
Pharma company Corona Remedies is set to further bolster its presence in cardiology and hormones for women with seven major brands purchased from Bayer's Indian pharmaceuticals division. The acquisition would take effect on July 16, 2025, and is...
TrioTree Technologies, a leading healthcare IT solutions provider, has reached a major technological breakthrough with the successful deployment of its AI and NLP-powered voice-to-structured-data system across partner clinics. This cutting-edge...
.jpeg){kind=spacer}
AstraZeneca Pharma India has obtained an approval by the Central Drugs Standard Control Organisation (CDSCO) to import and market Durvalumab solution for infusion with an expanded indication in India.
.png)
The US Food and Drug Administration (FDA) has granted new approval for Bayer’s finerenone (Kerendia) with a new indication to treat adults with heart failure and a left ventricular ejection fraction (LVEF) of 40% or higher...
On Tuesday, Aurobindo Pharma announced that it will produce and distribute cabotegravir, a long-acting injectable HIV therapy, in 133 nations. According to a statement from the firm, the Hyderabad-based pharmaceutical company has been chosen as on
The Top 10 Women Disruptors in Asia from the Pharmaceutical Industry who are creating new pathways for innovation and impact. These inspiring leaders are from various countries throughout the continent, imparting diverse views of the future of
AstraZeneca reported encouraging top-line results from the Phase III BaxHTN trial, demonstrating baxdrostat's statistically significant and clinically significant decrease in mean seated systolic blood pressure
, CDSCO.jpg)
